Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
Go back to Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus| (NASDAQ: AVIR) | Delayed: 5.26 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.26 | 52 Week High | $2.00 | |||
| Open | $5.21 | 52 Week Low | $1.15 | |||
| Day High | $5.29 | P/E | N/A | |||
| Day Low | $5.17 | EPS | $0.00 | |||
| Volume | 81,980 | |||||
